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ABSTRACT
Hematopoietic stem cell transplantation is currently the only curative therapy for -thalassemia major.
However, <30% of patients have unaffected HLA-identical siblings to serve as donors. We investigated the
feasibility of using umbilical cord blood transplants from unrelated HLA mismatched donors and a myeloab-
lative preparative regimen that did not involve total body irradiation. Between October 2003 and November
2004, 5 children with -thalassemia major received busulfan, cyclophosphamide, and antithymocyte globulin
before cord blood transplantation (median dose, 8.8  107 cells per kilogram of body weight) from unrelated
donors (1 or 2 of 6 HLA antigens were mismatched) and were then evaluated for engraftment, adverse effects,
and treatment outcome. The median times to neutrophil engraftment, red blood cell transfusion indepen-
dence, and platelet engraftment were 12, 34, and 46 days after transplantation, respectively. All patients showed
grade II or III acute graft-versus-host disease; none developed extensive chronic graft-versus-host disease until
the date of last contact. All patients were alive at a median follow-up of 303 days after transplantation, with
complete donor chimerism and transfusion independence. These results are encouraging and clearly show the
feasibility of unrelated mismatched umbilical cord blood transplantation in the treatment of children with
-thalassemia major.
© 2005 American Society for Blood and Marrow Transplantation
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DNTRODUCTION
The current conventional treatment of -thalas-
emia major consists of lifelong monthly blood trans-
usion combined with daily subcutaneous iron chela-
ion therapy with desferrioxamine from approximately
years of age onward [1,2]. The use of umbilical cord
lood (UCB) offers a potential means of alleviating
he shortage of donors that has plagued bone marrow
ransplantation since its inception [3-5]. Extending
he use of UCB to unrelated mismatched donor trans-
lants would greatly facilitate the identiﬁcation and
rocurement of the pluripotent stem cells required for
ematopoietic stem cell transplantation (HSCT) for t
B&MTarge numbers of patients for whom no acceptable
amily donor is available.
ATERIALS AND METHODS
atients
Five consecutive patients with -thalassemia ma-
or underwent transplantation with a UCB graft at
hang Gung Children’s Hospital between October
003 and August 2004. The diagnosis of each
-thalassemia major participant was conﬁrmed by
NA sequencing. These patients were enrolled ontohis study because they had neither an HLA-identical
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3elated donor nor a related donor with 2 HLA mis-
atches, and an HLA-matched, unrelated bone mar-
ow donor could not be located within 6 months. The
edian age at transplantation was 3.7 years (range,
.3-11.4 years). This study was approved by both the
nstitutional Review Board at Chang Gung Memorial
ospital and the Department of Health of Taiwan.
ord Blood Selection and Characteristics
The compatibility of HLA-A, -B, and -DRB1 was
ssessed by a high-resolution polymerase chain reac-
ion technique with sequence-speciﬁc primers. Cord
lood units were selected on the basis of HLA com-
atibility (a minimum of 4 HLA antigens shared with
he recipient was required, and only 1 HLA-DRB1
ingle-locus mismatch was allowed). The selected
ord blood had to contain, per kilogram of the recip-
ent’s body weight, at least 2 107 nucleated cells and
.7  105 CD34 cells (determined at the time of
ryopreservation). Searches for unrelated cord blood
onors were processed through the StemCyte Cord
lood Bank, where 12 000 cord blood units are avail-
ble locally in Taiwan.
onditioning Regimen and Transplantation
rocedure
Before the UCB transplantation procedure, all pa-
ients were placed in a high-efﬁciency particulate air–
ltered room in the bone marrow transplantation unit.
he preparative regimens consisted of oral busulfan
.5 mg/kg/d (day 9 to 6), intravenous cyclophos-
hamide 50 mg/kg/d (day 5 to 2), and antithymo-
yte globulin (Pharmacia-Upjohn, Peapack, NJ) 30
g/kg/d (day 4 to 1). Patients received phenytoin
or prophylaxis against seizures during treatment.
esna 50 mg/kg was administered intravenously on
he days of cyclophosphamide infusion. Graft-versus-
ost disease prophylaxis comprised cyclosporine (2.5
g/kg intravenously every 8 hours) from day 3 with
course of methylprednisolone (1 mg/kg intrave-
ously every 12 hours on days 5 to 19, decreasing 25%
hereafter every other day). The cyclosporine dose
ay be tapered beginning at least 60 days after dem-
nstration of engraftment and full donor chimerism
y short tandem repeat (STR) analysis.
In this study, 4 patients received 1 unit of cord
lood, whereas 1 patient received 2 units. However,
he DNA of only 1 of the 2 donors was detectable after
ngraftment. The numbers of infused nucleated and
rogenitor cells are shown in Table 1. The UCB units
ere thawed in a 37°C waterbath with gentle agitation
nd without further processing before infusion into
he patients. Granulocyte colony-stimulating factor
ﬁlgrastim; Kirin, Gunma, Japan) 10 g/kg/d was
iven intravenously on day 1 after transplantation and
n each day thereafter until the neutrophil count re-mained 1.0  109/L for 3 consecutive days.Ta Cl
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Unrelated Mismatched Cord Blood Transplantation in -Thalassemia Major
Bupportive Care and Posttransplantation
ollow-up
Blood components were given whenever indicated
o maintain hemoglobin and platelet values 8 g/dL
nd 20  109/L, respectively. For streptococcal pro-
hylaxis, intravenous cefazolin was given until the
eutrophil counts exceeded 0.5  109/L, and oral
traconazole (antifungal prophylaxis) 3 mg/kg daily
as prescribed for the month preceding transplanta-
ion. Intravenous or oral acyclovir and oral co-trimox-
zole were given to prevent cytomegalovirus (CMV)
eactivation and Pneumocystis carinii infection. Both
cyclovir and co-trimoxazole were continued as pro-
hylaxis until day 180 after transplantation and may be
ontinued until T-cell function is restored. Parenteral
utrition was provided for the duration of anorexia.
ntravenous immunoglobulin (500 mg/kg) was given
t day 6, 7, 21, 35, 56, 77, and 98 after
CB transplantation. The standard CMV pp65 anti-
enemia assay was performed in parallel. The positive
esults were quantiﬁed by counting the number of
p65-expressing cells per 50 000 leukocytes on the
lide.
Myeloid engraftment was deﬁned as 3 consecutive
ays of an absolute neutrophil count of0.5 109/L.
he last day of red blood cell (RBC) transfusion was
ecorded as a day of RBC transfusion independence.
latelet engraftment was deﬁned as 7 consecutive days
f a platelet count 50  109/L maintained without
ransfusion. Current methods for measuring hemato-
oietic chimerism are based on STR polymorphisms
hat distinguish recipient from donor. Serial STR
olymerase chain reaction conﬁrmed the conversion
rom mixed chimerism to a predominantly donor pro-
le on day 60, 90, 120, 180, 270, and 360,
ollowed by quarterly for the second year after trans-
lantation and yearly thereafter. In the subset of pa-
able 2. Characteristics of Engraftment, GVHD Grading, Outcome, a
Variable 1 2
ays until
ANC >0.5  109/L 17 12
RBC transfusion
independence 34 37
Platelets >20  109/L 49 46
VHD grade I II
utcome
Transfusion
independence
Transfusion
independe
ays after
transplantation 454 344
ay of the last
chimerism 360 270
himerism analysis
(% donor cells) 100 100
NC indicates absolute neutrophil count; RBC, red blood cell.
Double cord blood transplantation.
B&MTients with heavy iron overload who achieved myeloid
ngraftment, desferrioxamine was administered at 40
g/kg/d as a 24-hour intravenous infusion to acceler-
te the clearance of body iron deposits.
ESULTS
ngraftment and Immune Reconstitution
High-resolution molecular typing demonstrated
hat 2 recipient/donor pairs had HLA 2-loci mis-
atches, and the remaining 3 pairs had a mismatch at
locus. However, neither delayed myeloid engraft-
ent nor an increased incidence of early transplant
omplications was observed. Neutrophil engraftment
ccurred at a median of 12 days (range, 12-17 days)
fter transplantation. The median day to RBC trans-
usion independence was 34 days (range, 22-45 days).
he median number of days to achieve a platelet
ount of20 109/L was 46 days (range, 43-55 days;
able 2). Serum immunoglobulin levels were in the
eference range 6 months after transplantation.
In the ﬁfth patient, double cord blood units were
sed to minimize the risk of developing graft failure in
his multiply transfused patient, who weighed30 kg.
owever, the graft was derived from a female donor
ith a higher cell dose and better matching. All pa-
ients with myeloid engraftment showed complete do-
or chimerism by day 17 at the time of ﬁrst STR
NA analysis. These data support the notion that
ertain HLA differences do not affect the clinical
utcome of UCB transplantations and conﬁrm the
otential beneﬁt of using unrelated donor UCB for
-thalassemia major.
ransplantation-Related Events
All patients developed acute graft-versus-host dis-
ase. Asymptomatic CMV reactivation was detected in
erism
Patient
3 4 5*
14 12 12
27 45 22
43 43 55
I II III
Transfusion
independence
Transfusion
independence
Transfusion
independence
303 245 152
270 180 120
100 100 100nd Chim
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3patients (patients 2 and 5) on posttransplantation
ays 27 and 62, respectively. They were successfully
reated preemptively with intravenous ganciclovir. Pa-
ient 2 experienced 2 episodes of reactivation during
ollow-up, and the disease status remained quiescent
fter cyclosporine was stopped 7 months after trans-
lantation. Both patients are still taking oral acyclovir
rophylactically at the time of this report. According
o the criteria outlined previously, continuous chela-
ion therapy was administered with desferrioxamine in
nly 1 patient (patient 5) during the early posttrans-
lantation period.
verage Cost per Admission
The per-patient medical expense for UCB trans-
lantation is estimated to be approximately US
40 000 plus the cost of the cord blood (which was
aived for our patients).
ISCUSSION
-Thalassemia major often causes transfusion-re-
ated complications, which have a major economic
nd even political impact. Banked, unrelated, partially
LA-matched UCB is an alternative stem cell source
or patients in need of transplantation therapy who
ack traditionally matched donors. Full HLA compat-
bility is desirable in HSCT, but mismatches of 1, 2, or
antigens are acceptable with UCB [6]. Because sev-
ral clinical studies have demonstrated improved sur-
ival after infusion of higher cell doses per kilogram of
ody weight, cord blood units containing high cell
oses were chosen for our study [7-9].
Traditional techniques for HSCT rely on the pro-
uction of biologic “space” in the recipient’s bone
arrow compartment by myeloablative conditioning.
major disadvantage to myeloablative conditioning is
transient period of myelosuppression before bone
arrow reconstitution, during which the bone mar-
ow transplant recipient is susceptible to infection.
ngraftment usually seems slower after transplanta-
ion of cord blood than marrow or peripheral blood
4,10,11]. A consensus is emerging that UCB grafts of
igher cell doses should be selected wherever possible
o optimize engraftment [12]. It is noteworthy that the
CB we used in this study (which had a higher num-
er of CD34 cells or total nucleated cells) led to earlier
eutrophil recovery. We attribute these good results
o the fact that all the thalassemia patients included in
he study were classiﬁed as Lucarelli class I. The use of
higher dose of growth factor (10 g/kg/d) may also
ave contributed to speedy engraftment. UCB con-
ains enough hematopoietic stem cells to reconstitute
one marrow in children. Moreover, Wagner et al. [7]
uggested that a higher CD34 cell dose partially over-
52omes the negative effect of UCB with 2 HLA
isparities.
Iron overload is frequent in patients with -thalas-
emia major and after UCB transplantation; it is often
aused by ineffective erythropoiesis, intestinal hyper-
bsorption, and RBC transfusions. Relatively little is
nown about the reconstitution of hematopoiesis in
halassemia after transplantation. In our study, the
ollow-up electrophoresis in the ﬁrst patient identiﬁed
nly small amounts of hemoglobin F (16.1% and
.6%) 6 and 12 months after transplantation, respec-
ively. HSCT acts as a double-edged sword. Some
halassemia patients may develop either mixed chi-
erism or late rejection 1 year after transplantation,
ut others may die prematurely or experience delayed
ecovery [13,14]. The success of UCB transplantation
n our study strongly suggested that ideal candidates
or HSCT are young patients without underlying
omplications of their disease or transfusional iron
verload.
HSCT with donors other than HLA-identical sib-
ings is associated with high morbidity and poor sur-
ival [15]. UCB transplantation seems to have a higher
isk of nonengraftment and secondary rejection [16-
8]. A more intensive conditioning regimen might
revent early graft failure [19]. Our conditioning reg-
mens have been generally well tolerated, and all pa-
ients showed myeloid engraftment by day 17 after
ransplantation. All patients had sustained engraft-
ent. Our result conﬁrmed previous ﬁndings on the
ssociation of nucleated cell dose with the speed and
robability of engraftment [20]. In addition, this study
resents recommendations to policy makers for inte-
rating unrelated mismatched UCB transplantation
nto health promotion initiatives.
The transplantation of unrelated mismatched
CB is highly valuable for patients with -thalassemia
ajor who have no HLA-suitable sibling donor, and it
s clearly cost-effective when compared with conven-
ional treatment with blood transfusions and iron che-
ation therapy. In summary, our results demonstrate
he importance of the graft cell dose in accelerating
ngraftment of UCB transplants, even in recipients
ho receive grafts disparate for 2 HLA loci.
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